RT Book, Section
A1 Gruenberg, Katherine
A1 Guglielmo, B. Joseph
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1184154289
T1 Oxazolidinediones
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1184154289
RD 2024/04/24
AB Oxazolidinediones  represent  a  class  of  antibacterials  including  linezolid  and  tedizolid.  These  agents  are  primarily  active  against  aerobic  gram-positive  pathogens,  including  penicillin-resistant  pneumococci,  methicillin-resistant  staphylococci  and  enterococci  (both  E  faecalis  and  vancomycin-sensitive  and  vancomycin-resistant  E  faecium),  and  mycobacteria.  Linezolid  is  bacteriostatic  against  all  of  these  pathogens.  Linezolid-resistant  enterococci  and  VRE  and  linezolid-resistant  S  aureus  and  S  epidermidis  have  been  isolated.  The  oral  bioavailability  of  these  medications  is  complete,  with  serum  levels  approaching  those  observed  with  intravenous  administration.  The  medications  are  eliminated  primarily  by  nonrenal  mechanisms.  An  advantage  of  tedizolid  is  that  it  can  be  administered  once  daily,  whereas  linezolid  requires  twice-daily  dosing.